Elaine Siegfried

Oct 23, 2024 | jamanetwork.com | Amy S. Paller |Pedro Mendes-Bastos |Elaine Siegfried |Lawrence F. Eichenfield

Key PointsQuestion  Is the efficacy of upadacitinib maintained with long-term treatment with an acceptable adverse event profile in adolescents with moderate to severe atopic dermatitis?

Mar 20, 2024 | jamanetwork.com | Amy S. Paller |Barry Ladizinski |Pedro Mendes-Bastos |Elaine Siegfried

Reanalysis of Study After Removal of Participants in 1 Trial of Upadacitinib for Atopic Dermatitis Upadacitinib Treatment in Adolescents With Atopic Dermatitis Amy S. Paller, MD, MS; Barry Ladizinski, MD, MPH, MBA; Pedro Mendes-Bastos, MD; Elaine Siegfried, MD; Weily Soong, MD; Vimal H. Prajapati, MD; Peter Lio, MD; Jacob P. Thyssen, MD, PhD, DmSci; Eric L. Simpson, MD, MCR; Andrew M. Platt, PhD; Eliza M. Raymundo, MD; Jianzhong Liu, MD, MS; Brian M.

Feb 2, 2024 | onlinelibrary.wiley.com | Elaine Siegfried |Lara Lee |Jonathan M. Spergel |Randy Prescilla

1 INTRODUCTION Dupilumab is a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, as an immunomodulator. Current regulatory labeling recommends completing all age-appropriate immunizations before initiating dupilumab treatment and avoiding live vaccine administration during treatment.1, 2 The LIBERTY AD PRESCHOOL (Part A and B; NCT03346434) study prohibited live attenuated vaccine administration within 4 weeks before the baseline visit and during treatment.

Apr 12, 2023 | jamanetwork.com | Amy S. Paller |Barry Ladizinski |Pedro Mendes-Bastos |Elaine Siegfried

Key PointsQuestion  Does upadacitinib safely improve moderate-to-severe atopic dermatitis in adolescents? Findings  Among 552 adolescents participating in 3 randomized clinical trials, upadacitinib administered once daily was generally well tolerated through 16 weeks.